IntraPace Inc.

IntraPace Inc. is a health technology company that specializes in solutions for chronic disease management, focusing on diabetes and obesity through advanced digital health platforms that enable real-time patient monitoring and personalized care. IntraPace Inc. was founded in 2001 and is headquartered in San Jose, US.

The company focuses on health technology solutions for chronic disease management. IntraPace has completed a total of 8 deals, with the most recent deal occurring on August 23, 2013, during which the company raised USD 3. 34 mn in venture funding. IntraPace specializes in innovative health technology solutions focused on chronic disease management, particularly in the area of diabetes and obesity.

Their core product offerings include advanced digital health platforms that integrate with connected devices to monitor patient health metrics in real-time. These solutions aim to empower patients and healthcare providers by delivering actionable insights, enhancing treatment adherence, and facilitating personalized care plans. The company primarily serves healthcare providers, including hospitals and outpatient clinics, alongside direct end-users who are patients managing chronic conditions. IntraPace's products are marketed in North America and select European countries, targeting regions with a significant prevalence of chronic diseases and a demand for enhanced patient management solutions.

IntraPace generates revenue through a multifaceted business model that includes direct sales to healthcare providers as well as subscription-based services for ongoing patient monitoring and support. The company structures its transactions to encompass both B2B partnerships with healthcare institutions and direct-to-consumer offerings, enabling broader access to its technologies. Clients typically engage with IntraPace's products through tiered subscription plans that provide varying levels of service and device access, catering to different healthcare needs and budgets. Noteworthy offerings include their flagship digital health platform, which combines software and hardware solutions tailored for chronic disease patients, enhancing both engagement and health outcomes.

IntraPace plans to leverage recent funding to enhance its product offerings and expand its market reach. The company is currently designing new products aimed at further improving chronic disease management, with release dates expected to be announced in the near future. Additionally, IntraPace is targeting expansion into new markets in Europe, specifically regions experiencing high incidences of diabetes and obesity, by 2024. The funds raised in August 2013 amounting to USD 3.

34 mn will support these initiatives, facilitating product development and market entry.